New insights into how inhalational anesthetics induce general anesthesia

Since their anesthetic effects were discovered approximately 180 years ago, inhalational anesthetics have been used for general anesthesia in surgical operations. However, the mechanism of their anesthetic has not been fully revealed yet. Previous studies have shown that inhalational anesthetics exert their anesthetic effects by acting on multiple proteins, but the presence of unknown target molecules has also been suggested.

In rare cases, patients with abnormal type 1 ryanodine receptors (RyR1) (RyR1 mutations) have been known to be at higher risk of malignant hyperthermia, which can be caused by inhalational anesthetics. However, the direct molecular interaction between inhalational anesthetics and RyR1 has not been clearly demonstrated, and the relationship between RyR1 and anesthetic effects has also been unknown.

In the present study, a research group led by Professor Hiroki Ueda of the Graduate School of Medicine, The University of Tokyo, found that RyR1 which is a calcium release channel, induces general anesthesia by serving as a target molecule of inhalational anesthetics.

The research group first confirmed that isoflurane and other inhalational anesthetics activate RyR1 and stimulate calcium release from the endoplasmic reticulum. The amino acid residues in RyR1 which play an important role in the isoflurane-induced activation were identified, and the binding site of isoflurane was estimated. Additionally, the research group created a genetically modified mouse (knock-in mouse) which expressed the RyR1 mutant that does not respond to isoflurane. When the knock-in mice were exposed to isoflurane, they demonstrated a partially reduced sensitivity to anesthesia compared to normal mice.

Furthermore, new compounds that target the putative binding site of isoflurane were identified from in silico compound screening and were found to have sedative-like effects in mice. These results suggest that RyR1 is a functional target of isoflurane that is directly related to its anesthetic properties.

This research reveals one aspect of the molecular mechanism of inhalational anesthetics used for general anesthesia. This is a new finding as previous studies have not demonstrated the relationship between RyR1 and anesthetic effects in mammals. A more detailed understanding of anesthetics' mechanism of action could lead to the development of better anesthetics and treatment methods.
The results of this study were published in the online version of the American scientific journal PLOS Biology on June 3, 2025 (EDT).

This result was achieved in the Ueda Biological Timing Project, a research area of the Exploratory Research for Advanced Technology (ERATO) by the Japan Science and Technology Agency (JST). Under this project, JST pursues "systems biology for understanding humans" using the sleep-wake rhythm as a model system and aims to understand information on "biological time," which transcends from molecules to individual humans living in society.

Source:
Journal reference:

Kanaya, H. J., et al. (2025). Isoflurane activates the type 1 ryanodine receptor to induce anesthesia in mice. PLoS Biology. doi.org/10.1371/journal.pbio.3003172.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Breakthrough drug delivery system transports genetic therapies directly to the lungs